Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial

Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial

Invasive aspergillosis (IA) and mucormycosis (IM) cause significant morbidity and mortality in immunocompromised and/or hospitalized patients. Isavuconazonium sulfate, a prodrug of the antifungal triazole isavuconazole, has been approved for treatment of IA and IM in adults; and was recently approve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2024-12, Vol.68 (12)
Hauptverfasser: Segers, Heidi, Deville, Jaime G, Muller, William J, Manzanares, Angela, Desai, Amit, Neely, Michael, Bordon, Victoria, Hanisch, Benjamin, Lassaletta, Alvaro, Fisher, Brian T, Autmizguine, Julie, Groll, Andreas H, Sinnar, Shamim, Croos-Dabrera, Rodney, Engelhardt, Marc, Jones, Mark, Kovanda, Laura L, Arrieta, Antonio C
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Invasive aspergillosis (IA) and mucormycosis (IM) cause significant morbidity and mortality in immunocompromised and/or hospitalized patients. Isavuconazonium sulfate, a prodrug of the antifungal triazole isavuconazole, has been approved for treatment of IA and IM in adults; and was recently approved in children. This study describes the outcomes, safety, and pharmacokinetics of isavuconazole for the treatment of proven, probable, or possible IA or IM in children. In this phase 2, open-label, non-comparative study, patients aged 1 to
ISSN:0066-4804